Skip to main content

Baltimore Biotech Developing Diabetes Treatments Raises $20.5M

Glyscend Incorporated, a Baltimore-based biotechnology company out of Johns Hopkins University, has raised $20.5M in Series A funding to develop treatments for Type 2 Diabetes. According to theBaltimore Business Journal, the startup has been developing technologies that aim to recreate the effects of bariatric surgery for patients dealing with diabetes and obesity without the need for invasive procedures.

Read More

Michele Whelley - President & CEO

"We want you to be informed about Greater Baltimore. Don't be shy; please ask."

Michele Whelley
President & CEO

We are here to help you!

If you've landed on this site, then you have questions about us, and we want to help. We know that your time is crucial, and getting access to us should not be a complicated thing. Drop us a note via one of the options below and we will get back to you within 24 hours.

(410) 864-9927